These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7094507)

  • 1. Plasma steady-state concentrations of hydroxylated metabolites of clomipramine.
    Linnoila M; Insel T; Kilts C; Potter WZ; Murphy DL
    Clin Pharmacol Ther; 1982 Aug; 32(2):208-11. PubMed ID: 7094507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.
    Nielsen KK; Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1992; 43(4):405-11. PubMed ID: 1451721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Luscombe DK; Wright J; Stern RS; Mawson D; Marks IM
    Postgrad Med J; 1980; 56 Suppl 1():140-3. PubMed ID: 7393825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder.
    Mavissakalian M; Jones B; Olson S; Perel JM
    Psychopharmacol Bull; 1990; 26(1):119-22. PubMed ID: 2371366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomipramine: plasma levels, side effects and outcome in obsessive-compulsive neurosis.
    Stern RS; Marks IM; Wright J; Luscombe DK
    Postgrad Med J; 1980; 56 Suppl 1():134-9. PubMed ID: 7393824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine and exposure for compulsive rituals: II. Plasma levels, side effects and outcome.
    Stern RS; Marks IM; Mawson D; Luscombe DK
    Br J Psychiatry; 1980 Feb; 136():161-6. PubMed ID: 7370482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder.
    Flament MF; Rapoport JL; Murphy DL; Berg CJ; Lake CR
    Arch Gen Psychiatry; 1987 Mar; 44(3):219-25. PubMed ID: 3548637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment.
    Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C
    Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum clomipramine and metabolite levels in four nursing mother-infant pairs.
    Wisner KL; Perel JM; Foglia JP
    J Clin Psychiatry; 1995 Jan; 56(1):17-20. PubMed ID: 7836334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder.
    Marazziti D; Baroni S; Faravelli L; Giannaccini G; Massimetti G; Palego L; Catena-Dell'Osso M
    Int Clin Psychopharmacol; 2012 Jan; 27(1):55-60. PubMed ID: 21979789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies in obsessional patients.
    Luscombe DK; Marks IM
    J Int Med Res; 1977; 5 Suppl 5():91-6. PubMed ID: 598610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clomipramine in obsessive-compulsive ritualisers treated with exposure therapy: relations between dose, plasma levels, outcome and side effects.
    Kasvikis Y; Marks IM
    Psychopharmacology (Berl); 1988; 95(1):113-8. PubMed ID: 3133689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography.
    Banger M; Hermes B; Härtter S; Hiemke C
    Pharmacopsychiatry; 1997 Jul; 30(4):128-32. PubMed ID: 9271779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder.
    Kelly MW; Myers CW
    DICP; 1990; 24(7-8):739-44. PubMed ID: 2197816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation.
    Shimoda K; Noguchi T; Ozeki Y; Morita S; Shibasaki M; Someya T; Takahashi S
    Neuropsychopharmacology; 1995 Jul; 12(4):323-33. PubMed ID: 7576009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clomipramine in the elderly: tolerance and plasma levels.
    Kunik ME; Pollock BG; Perel JM; Altieri L
    J Geriatr Psychiatry Neurol; 1994; 7(3):139-43. PubMed ID: 7916936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data.
    Noguchi T; Shimoda K; Takahashi S
    J Affect Disord; 1993 Dec; 29(4):267-79. PubMed ID: 8126313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary report on clinical response and plasma levels of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
    Stern RS; Cobb JP; Marks IM; Jones RB; Luscombe DK
    Postgrad Med J; 1977; 53 Suppl 4():97-103. PubMed ID: 341110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.